A Phase 3 interventional study of Granulocyte colony-stimulating factor plus plerixafor and Granulocyte colony-stimulating factor plus placebo in Multiple Myeloma, sponsored by Genzyme, a Sanofi Company. Completed at 39 sites in 3 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2014-03-13.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.
Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 5 that started in 2005, is one of 2 in phase 3, and was the 3rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:
Guangzhou Gloria Biosciences Co., Ltd. · Sites in China
Ages 18–78
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 38 across the 28 interventional studies. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
39 studies in Multiple Myeloma by Sanofi: 3 open now, 8 under way, 3 of them phase 3. Of 30 finished, 12 (40%) have results posted.
Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2005, is one of 7 in phase 3, and was the 2nd registered.
Sanofi’s Multiple Myeloma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 39 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.
A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Currently filgrastim (G-CSF), a colony stimulating factor, is used to cause the growth and mobilization of stem cells from bone marrow to peripheral blood, which can then be collected from the peripheral blood by a process called apheresis. Plerixafor aids in the release of the stem cells from the bone marrow into the peripheral blood, possibly allowing for a more rapid collection of a larger number of stem cells from the peripheral blood. Larger stem cell doses for transplantation correlate to faster recovery times after high dose chemotherapy followed with stem cell transplantation. This study is intended to determine whether the combination of plerixafor with filgrastim (G-CSF)is better than filgrastim (G-CSF) alone in helping multiple myeloma patients collect at least 6 million stem cells in two or less apheresis sessions.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Granulocyte colony-stimulating factor plus plerixafor
Drug: Granulocyte colony-stimulating factor plus placebo
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Also known as: Mozobil, AMD3100
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.
Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 2 or fewer days of apheresis. Central lab data were taken from Days 5 to 6 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 2 apheresis days.
Time frame: up to Day 6
Number of Participants With Adverse Events
Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.
Time frame: up to Day 38
Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.
Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
Time frame: up to Day 8
Proportion of Participants Achieving a Target of ≥ 2*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.
Proportion of participants achieving a target of ≥ 2\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
Time frame: up to Day 8
Median Number of Days to ≥6*10^6 CD34+ Cells/kg
The Kaplan Meier estimate of median number of days (number of days at which 50% of participants have experienced the event, accounting for censored values) in each treatment arm to collect an optimum number of cells (≥6\*10\^6 CD34+ cells/kg) for transplantation.
Time frame: up to Day 8
Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment
The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.
Time frame: Up to Month 13
Median Number of Days to Platelet (PLT) Engraftment
The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.
Time frame: Up to Month 13
Graft Durability at 100 Days Post Transplantation
The proportion of participants maintaining a durable graft at 100 days post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
Time frame: approximately Day 138
Graft Durability at 6 Months Post Transplantation
The proportion of participants maintaining a durable graft at 6 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
Time frame: approximately Month 7
Graft Durability at 12 Months Post Transplantation
The proportion of participants maintaining a durable graft at 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
Time frame: approximately Month 13
Participants with multiple myeloma (MM) eligible for autologous hematopoietic stem cell transplant were recruited from 40 centers (38 in the U.S., 1 in Germany, 1 in Canada). The first participant was randomized on 04 February 2005 and the last participant's last study visit occurred on 22 January 2008. A total of 302 participants were randomized.
| Milestone | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Started | 148 | 154 |
| Completed | 129 | 121 |
| Not completed | 19 | 33 |
| Withdrew: Entered rescue procedure | 0 | 7 |
| Withdrew: Death | 7 | 7 |
| Withdrew: Elective withdrawal | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other | 6 | 9 |
| Withdrew: Failed mobilization | 0 | 4 |
| Withdrew: Intercurrent illness | 1 | 0 |
Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 2 or fewer days of apheresis. Central lab data were taken from Days 5 to 6 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 2 apheresis days.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion achieving target in ≤2 days | 0.716 | 0.344 |
| Proportion not achieving target in ≤2 days | 0.284 | 0.656 |
Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.
| participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Adverse Events (AEs) | 140 | 140 |
| Related AEs | 95 | 67 |
| AEs Leading to early treatment termination | 1 | 2 |
| AEs Leading to early termination | 3 | 0 |
| Grade 3 (severe) or 4 (life-threatening) AEs | 11 | 11 |
| Serious Adverse Events (SAEs) | 4 | 6 |
Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion achieving target in ≤4 days | 0.757 | 0.513 |
| Proportion not achieving target in ≤4 days | 0.243 | 0.487 |
Proportion of participants achieving a target of ≥ 2\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion achieving target in ≤4 days | 0.953 | 0.883 |
| Proportion not achieving target in ≤4 days | 0.047 | 0.117 |
The Kaplan Meier estimate of median number of days (number of days at which 50% of participants have experienced the event, accounting for censored values) in each treatment arm to collect an optimum number of cells (≥6\*10\^6 CD34+ cells/kg) for transplantation.
| Days | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Median Number of Days to ≥6*10^6 CD34+ Cells/kg | 1.0 (1.0 to 2.0) | 4.0 (2.0 to NA) |
The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.
| Days | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment | 11.0 (10.0 to 12.0) | 11.0 (11.0 to 12.0) |
The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.
| Days | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Median Number of Days to Platelet (PLT) Engraftment | 18.0 (16.0 to 22.0) | 18.0 (16.0 to 21.0) |
The proportion of participants maintaining a durable graft at 100 days post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion of participants with a durable graft | 0.986 | 0.978 |
| Proportion of participants without a durable graft | 0.014 | 0.022 |
The proportion of participants maintaining a durable graft at 6 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion of participants with a durable graft | 0.985 | 0.984 |
| Proportion of participants without a durable graft | 0.015 | 0.016 |
The proportion of participants maintaining a durable graft at 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion of participants with a durable graft | 0.992 | 0.992 |
| Proportion of participants without a durable graft | 0.008 | 0.008 |
Collected over Day 1 (start of G-CSF Mobilization plus Treatment/Apheresis) to the day before starting chemotherapy. Chemotherapy typically started within 30 days of the last apheresis (which may have occurred on Day 5, 6, 7, or 8).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-CSF Plus Plerixafor | — | 4/147 (2.7%) | 140/147 (95.2%) |
| G-CSF Plus Placebo | — | 6/151 (4%) | 140/151 (92.7%) |
| Event | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 0/147 | 2/151 |
| Atrial fibrillationCardiac disorders | 1/147 | 0/151 |
| Bone painMusculoskeletal and connective tissue disorders | 1/147 | 1/151 |
| HemiparesisNervous system disorders | 1/147 | 0/151 |
| Deep vein thrombosisVascular disorders | 1/147 | 0/151 |
| VomitingGastrointestinal disorders | 0/147 | 1/151 |
| Enterobacter bacteraemiaInfections and infestations | 0/147 | 1/151 |
| DehydrationMetabolism and nutrition disorders | 0/147 | 1/151 |
| Muscle spasticityNervous system disorders | 0/147 | 1/151 |
| AgitationPsychiatric disorders | 0/147 | 1/151 |
| Event | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Bone painMusculoskeletal and connective tissue disorders | 53/147 | 64/151 |
| NauseaGastrointestinal disorders | 51/147 | 39/151 |
| DiarrhoeaGastrointestinal disorders | 47/147 | 29/151 |
| FatigueGeneral disorders | 40/147 | 41/151 |
| HeadacheNervous system disorders | 30/147 | 35/151 |
| Back painMusculoskeletal and connective tissue disorders | 23/147 | 34/151 |
| ParaesthesiaNervous system disorders | 33/147 | 34/151 |
| Injection site erythemaGeneral disorders | 32/147 | 5/151 |
| HypokalaemiaMetabolism and nutrition disorders | 19/147 | 29/151 |
| Catheter site painGeneral disorders | 14/147 | 19/151 |
| Age, Continuous(years) | G-CSF Plus Plerixafor | G-CSF Plus Placebo | Total |
|---|---|---|---|
| Mean | 58.2 ± 8.4 | 58.4 ± 8.6 | 58.3 ± 8.5 |
| Sex: Female, Male(Participants) | G-CSF Plus Plerixafor | G-CSF Plus Placebo | Total |
|---|---|---|---|
| Female | 48 | 47 | 95 |
| Male | 100 | 107 | 207 |
| Race/Ethnicity, Customized(participants) | G-CSF Plus Plerixafor | G-CSF Plus Placebo | Total |
|---|---|---|---|
| Caucasian | 117 | 128 | 245 |
| African-American | 18 | 14 | 32 |
| Asian | 1 | 3 | 4 |
| Hispanic/Latino | 11 | 4 | 15 |
| Other | 1 | 5 | 6 |
The record gives a start of Jan 2005, a primary completion of Oct 2006 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor